Saturday, October 31, 2026

USD/CNH Bullish Momentum: 0.99% Up In The Last 10 Sessions

USD/CNH Bullish Momentum: 0.99% Up In The Last 10 Sessions

(VIANEWS) - USD/CNH (USDCNH) has been up by 0.99% for the last 10 sessions. At 20:08 EST on Tuesday, 23 April, USD/CNH (USDCNH) is $7.26.

USD/CNH's yearly highs and lows, it's 0.011% up from its 52-week low and 0.025% down from its 52-week high.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, USD/CNH's Forex is considered to be overbought (>=80).

News about

  • According to FXStreet on Tuesday, 23 April, "The US Dollar (USD), on the other hand, remains well within the striking distance of its highest level since November set last week amid hawkish Fed expectations and turns out to be another factor acting as a tailwind for the USD/JPY pair. ", "From a technical perspective, the Relative Strength Index (RSI) is still flashing overbought conditions on the daily chart and holding back the USD/JPY pair from placing fresh bets. "
  • According to FXStreet on Tuesday, 23 April, "Slowing trend inflation measure could pour cold water on the next BoJ rate hike bets, as USD/JPY reverts toward the multi-decade highs of 154.85 reached during early Asian hours."
  • According to FXStreet on Tuesday, 23 April, "The USD/JPY pair is trading at 154.75, losing 0.06% on the day at the time of writing."
  • According to FXStreet on Tuesday, 23 April, "Analysts at Rabobank share their outlook for USD/JPY ahead of the Bank of Japan's (BoJ) policy meeting later in the week.", "Our 3 month USD/JPY 148 forecast assumes that the Fed will be laying the groundwork for a September rate cut during the summer."

More news about USD/CNH (USDCNH).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com